{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:47:50Z","timestamp":1782362870942,"version":"3.54.5"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The population pharmacokinetic (PK) modeling of vancomycin has been validated to accurately predict concentration\u2013time data in sepsis patients, but its effectiveness in clinical practice remains uncertain. This study aims to evaluate the clinical utility of individualized vancomycin dosing guided by a population PK model in patients with severe infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-center, randomized, single-blind, controlled clinical trial. A total of 54 participants with severe infections caused by suspected or confirmed Gram-positive bacteria, who received vancomycin treatment during hospitalization, were prospectively included and identified as eligible. Participants were randomly allocated to either the individualized dosing group guided by a population PK model (n = 28) or the empirical dosing group (n = 26). After a 2-week treatment period, comparisons were made regarding pharmacokinetics\/pharmacodynamics (PK\/PD) target attainment, clinical efficacy, and safety between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The individualized dosing group achieved an area under the concentration curve (AUC\n                      <jats:sub>24<\/jats:sub>\n                      ) target rate of 69.23%, while the empirical dosing group had a rate of 8.33% (p = 0.000). Significant differences were also observed in body temperature, white blood cell count, Glasgow Coma Scale (GCS) score, and Acute Physiology and Chronic Health Evaluation (APACHE) II score after the 2-week treatment period between the two groups (p &amp;lt; 0.05). No significant difference in adverse events was found between the two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A daily dosage of individualized administration guided by a population PK model results in improved attainment rates for PK\/PD targets and enhanced clinical efficacy without an increased risk of drug-related adverse reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/study\/NCT06161870<\/jats:ext-link>\n                      , identifier NCT06161870.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1852589","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:21:21Z","timestamp":1782361281000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective evaluation of individualized vancomycin dosing based on a population pharmacokinetic model in patients with severe Gram-positive bacterial infection"],"prefix":"10.3389","volume":"17","author":[{"given":"Qile","family":"Xiao","sequence":"first","affiliation":[{"name":"Department of Neurology, Second Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Second Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Second Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hainan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Second Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Second Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Second Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Second Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Second Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihua","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Second Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/phar.2722","article-title":"Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: systematic review and meta-analysis","volume":"42","author":"Abdelmessih","year":"2022","journal-title":"Pharmacotherapy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijantimicag.2018.09.021","article-title":"Plasma and interstitial fluid population pharmacokinetics of vancomycin in critically ill patients with sepsis","volume":"53","author":"Abraham","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s12028-019-00856-8","article-title":"Health care-associated infections in a neurocritical care unit of a developing country","volume":"32","author":"Abulhasan","year":"2020","journal-title":"Neurocrit Care"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3390\/antibiotics12091441","article-title":"The significance of Bayesian pharmacokinetics in dosing for critically ill patients: a primer for Clinicians using vancomycin as an example","volume":"12","author":"Alnezary","year":"2023","journal-title":"Antibiot. (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jiac.2015.02.001","article-title":"Applications of the pharmacokinetic\/pharmacodynamic (PK\/PD) analysis of antimicrobial agents","volume":"21","author":"As\u00edn-Prieto","year":"2015","journal-title":"J. Infect. Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s40262-018-0636-7","article-title":"Augmented renal clearance in critically ill patients: a systematic review","volume":"57","author":"Bilbao-Meseguer","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/jac\/dky543","article-title":"CSF penetration of vancomycin in critical care patients with proven or suspected ventriculitis: a prospective observational study","volume":"74","author":"Blassmann","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"300060520949076","DOI":"10.1177\/0300060520949076","article-title":"Effect of augmented renal clearance on the therapeutic drug monitoring of vancomycin in patients after neurosurgery","volume":"48","author":"Chen","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/sur.2019.031","article-title":"Incidence and risk factors associated with multi-drug-resistant pathogens in a critically ill trauma population: a retrospective cohort study","volume":"21","author":"Cucci","year":"2020","journal-title":"Surg. Infect. (Larchmt)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"30388","DOI":"10.1016\/j.cmi.2020.07.005","article-title":"Towards precision dosing of vancomycin in critically ill patients: an evaluation of the predictive performance of pharmacometric models in ICU patients","author":"Cunio","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"B11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s12028-014-0045-1","article-title":"Kidney-brain link in traumatic brain injury patients? A preliminary report","volume":"22","author":"Dias","year":"2015","journal-title":"Neurocrit Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1002\/bcp.70185","article-title":"Dose individualisation of antibiotics in critically ill patients with inflammation: a narrative review","volume":"91","author":"Dr\u00e4ger","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e25616","DOI":"10.7759\/cureus.25616","article-title":"Pneumonia in nervous system injuries: an analytic review of literature and recommendations","volume":"14","author":"Erfani","year":"2022","journal-title":"Cureus"},{"key":"B14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40262-018-0707-9","article-title":"Monitoring of tobramycin exposure: what is the best estimation method and sampling time for clinical practice?","volume":"58","author":"Gao","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e02543","DOI":"10.1128\/AAC.02543-18","article-title":"External evaluation of population pharmacokinetic models of vancomycin in large cohorts of intensive care unit patients","volume":"63","author":"Guo","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s11095-024-03728-9","article-title":"Predictive value of vancomycin AUC24\/MIC ratio for 30-day mortality in patients with severe or complicated methicillin-resistant Staphylococcus aureus infections: a multicenter retrospective study","volume":"41","author":"Hanai","year":"2024","journal-title":"Pharm. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.21037\/tau-20-1048","article-title":"A higher dose of vancomycin is needed in critically ill patients with augmented renal clearance","volume":"9","author":"He","year":"2020","journal-title":"Transl. Androl. Urol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00228-019-02694-1","article-title":"Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?","volume":"75","author":"Heffernan","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"100970","DOI":"10.1016\/j.accpm.2021.100970","article-title":"A personalised approach to antibiotic pharmacokinetics and pharmacodynamics in critically ill patients","volume":"40","author":"Heffernan","year":"2021","journal-title":"Anaesth. Crit. Care Pain Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1001\/jama.2014.9743","article-title":"Clinical management of Staphylococcus aureus bacteremia: a review","volume":"312","author":"Holland","year":"2014","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Int. Suppl."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1111\/bcp.15429","article-title":"Risk factors for vancomycin-associated acute kidney injury: a systematic review and meta-analysis","volume":"88","author":"Kim","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/cpt.2203","article-title":"Key challenges in providing effective antibiotic therapy for critically ill patients with bacterial sepsis and septic shock","volume":"109","author":"Landersdorfer","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1471-2369-13-124","article-title":"High creatinine clearance in critically ill patients with community-acquired acute infectious meningitis","volume":"13","author":"Lautrette","year":"2012","journal-title":"BMC Nephrol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/cid\/ciz460","article-title":"The emperor's new clothes: prospective observational evaluation of the association between initial VancomycIn exposure and failure rates among ADult HospitalizEd patients with methicillin-resistant Staphylococcus aureus bloodstream infections (PROVIDE)","volume":"70","author":"Lodise","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s12028-018-0568-y","article-title":"Infection prevention in the neurointensive care unit: a systematic review","volume":"31","author":"Lord","year":"2019","journal-title":"Neurocrit Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s12028-015-0127-8","article-title":"Augmented renal clearance in patients with subarachnoid hemorrhage","volume":"23","author":"May","year":"2015","journal-title":"Neurocrit Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s12028-023-01714-4","article-title":"Creatinine clearance in acute brain injury: a comparison of methods","volume":"39","author":"Monteiro","year":"2023","journal-title":"Neurocrit Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40560-019-0408-y","article-title":"Enhanced renal clearance and impact on vancomycin pharmacokinetic parameters in patients with hemorrhagic stroke","volume":"7","author":"Morbitzer","year":"","journal-title":"J. Intensive Care"},{"key":"B30","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/CCM.0000000000003716","article-title":"Enhanced renal clearance in patients with hemorrhagic stroke","volume":"47","author":"Morbitzer","year":"","journal-title":"Crit. Care Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3947\/ic.2020.52.4.573","article-title":"Vancomycin area under the curve and pharmacokinetic parameters during the first 24 hours of treatment in critically ill patients using Bayesian forecasting","volume":"52","author":"Pongchaidecha","year":"2020","journal-title":"Infect. Chemother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1128\/AAC.01708-10","article-title":"Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens","volume":"55","author":"Roberts","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13054-022-04098-7","article-title":"Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trial","volume":"26","author":"Roggeveen","year":"2022","journal-title":"Crit. Care"},{"key":"B35","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the infectious diseases society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B36","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.cmi.2023.03.018","article-title":"Individualized antimicrobial dose optimization: a systematic review and meta-analysis of randomized controlled trials","volume":"29","author":"Sanz-Codina","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"B37","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1186\/s12879-025-11400-9","article-title":"Association of vancomycin trough levels, AUC and AUC\/MIC ratios with clinical outcomes in patients with enterococcal bacteremia: a prospective cohort study","volume":"25","author":"Sel","year":"2025","journal-title":"BMC Infect. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40780-025-00425-6","article-title":"Pharmacokinetic variability and significance of therapeutic drug monitoring for broad-spectrum antimicrobials in critically ill patients","volume":"11","author":"Tanaka","year":"2025","journal-title":"J. Pharm. Health Care Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12879-024-10399-9","article-title":"Impact of vancomycin area under the curve in early or later phase on efficacy and nephrotoxicity in patients with enterococcal bloodstream infections: a multicenter study","volume":"25","author":"Tangvichitrerk","year":"2025","journal-title":"BMC Infect. Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.3390\/jcm13082317","article-title":"The impact of augmented renal clearance on vancomycin pharmacokinetics and pharmacodynamics in critically ill patients","volume":"13","author":"Tesfamariam","year":"2024","journal-title":"J. Clin. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s00134-020-05950-6","article-title":"Bloodstream infections in critically ill patients: an expert statement","volume":"46","author":"Timsit","year":"2020","journal-title":"Intensive Care Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/ejhpharm-2022-003672","article-title":"Pharmacokinetic\/pharmacodynamic analysis of vancomycin in patients with Enterococcus faecium bacteremia: a retrospective cohort study","volume":"31","author":"Tochikura","year":"2024","journal-title":"Eur. J. Hosp. Pharm."},{"key":"B43","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1001\/jama.2025.4288","article-title":"Management of Staphylococcus aureus bacteremia: a review","volume":"334","author":"Tong","year":"2025","journal-title":"JAMA."},{"key":"B44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12879-021-05858-6","article-title":"The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing","volume":"21","author":"Tsutsuura","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1089\/neu.2015.4328","article-title":"Augmented renal clearance in traumatic brain injury: a single-center observational study of atrial natriuretic peptide, cardiac output, and creatinine clearance","volume":"34","author":"Udy","year":"2017","journal-title":"J. Neurotrauma"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1097\/TA.0000000000002492","article-title":"Vancomycin dosing in critically ill trauma patients: the VANCTIC study","volume":"87","author":"Villanueva","year":"2019","journal-title":"J. Trauma Acute Care Surg."},{"key":"B47","doi-asserted-by":"publisher","first-page":"835557","DOI":"10.3389\/fphar.2022.835557","article-title":"Augmented renal clearance in severe Infections-An important consideration in vancomycin dosing: a narrative review","volume":"13","author":"Xiao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3390\/antibiotics11070837","article-title":"Association between augmented renal clearance and inadequate vancomycin pharmacokinetic\/pharmacodynamic targets in Chinese adult patients: a prospective observational study","volume":"11","author":"Zhao","year":"2022","journal-title":"Antibiot. (Basel)"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1852589\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:21:22Z","timestamp":1782361282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1852589\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":48,"alternative-id":["10.3389\/fphar.2026.1852589"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1852589","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"article-number":"1852589"}}